Penicillin Allergy — Delabeling Pathways

Key Points

• A penicillin allergy label is a history that should be evaluated, not automatically accepted as lifelong allergy.
• Many labels reflect nonallergic adverse effects, viral exanthems, family history, or remote benign reactions.
• Direct oral amoxicillin challenge is appropriate for many carefully selected low-risk patients.
• Recent or convincing immediate urticaria, angioedema, bronchospasm, hypotension, or anaphylaxis may require skin testing before challenge.
• Penicillin skin testing evaluates immediate IgE-mediated risk and does not rule out severe delayed reactions.
• SJS, TEN, DRESS, AGEP, interstitial nephritis, hepatitis, hemolytic anemia, and other serious delayed reactions are not routine challenge candidates.
• Desensitization creates temporary tolerance and does not by itself remove the allergy diagnosis.
• A successful delabeling process requires updating the EHR and communicating tolerance so the label does not reappear.

Algorithm

1. Clarify the exact culprit drug, reaction features, timing after dose, treatment required, date of reaction, and later beta-lactam exposures.
2. Identify nonallergic histories such as isolated gastrointestinal symptoms, headache, family history only, or documented subsequent tolerance.
3. Screen specifically for severe delayed reactions, mucosal disease, blistering, eosinophilia, organ injury, cytopenia, nephritis, or hepatitis.
4. If severe delayed hypersensitivity is suspected, avoid routine challenge and refer for specialist evaluation.
5. If the history is low risk and challenge-eligible, perform a supervised oral amoxicillin challenge using the local protocol.
6. If the history suggests meaningful immediate IgE-mediated risk, consider penicillin skin testing followed by oral challenge if negative.
7. Treat any challenge reaction promptly according to severity, including intramuscular epinephrine for anaphylaxis.
8. After a tolerated challenge, remove the allergy label and document the drug, dose, date, and absence of reaction.

Clinical Synopsis & Reasoning

A penicillin allergy label should be treated as a diagnostic problem rather than a permanent fact. Many labels originate from childhood viral rashes, gastrointestinal adverse effects, family history, nonspecific symptoms, or reactions that occurred decades earlier and have never been reevaluated. Even genuine IgE-mediated penicillin sensitivity often wanes with time. The consequence of leaving an inaccurate label in place is clinically important because patients are more likely to receive broader-spectrum, less effective, more toxic, or more expensive alternatives and may face higher risks of resistant infection, Clostridioides difficile infection, surgical-site infection, and prolonged hospitalization.

Risk stratification depends on the phenotype, timing, severity, treatment required, and time elapsed since the index event. Histories such as isolated nausea, diarrhea, headache, yeast infection, family history alone, or a patient who has subsequently tolerated a penicillin are not compatible with current IgE-mediated allergy and may permit delabeling by history after careful documentation. Remote, benign cutaneous reactions without mucosal involvement, systemic illness, blistering, organ injury, or anaphylaxis are frequently considered low risk and are increasingly evaluated with direct oral amoxicillin challenge without preceding skin testing in appropriate supervised settings.

Features that raise concern for an immediate IgE-mediated reaction include urticaria, angioedema, bronchospasm, hypotension, or anaphylaxis beginning within minutes to several hours of a penicillin dose. Patients with these histories, especially if recent or severe, may need allergist-directed penicillin skin testing followed by oral challenge if testing is negative. Skin testing evaluates immediate hypersensitivity and does not predict severe delayed reactions.

A fundamentally different pathway applies to severe delayed immune-mediated reactions. Histories of Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, acute generalized exanthematous pustulosis, drug-induced hepatitis, interstitial nephritis, hemolytic anemia, or another serious organ-specific immune reaction should not be evaluated with routine oral challenge or desensitization merely to remove a label. The suspected culprit and potentially related drugs require specialist assessment and durable documentation. Distinguishing these phenotypes is the most important safety step in penicillin delabeling.

Treatment Strategy & Disposition

For a very low-risk history, delabel by history when the record clearly documents a nonallergic adverse effect, family history only, or subsequent uneventful penicillin exposure. When low-risk allergy remains possible, a supervised direct oral amoxicillin challenge is the preferred definitive test in many current pathways. Protocols vary by institution and may use a single therapeutic dose or a graded challenge, with observation long enough to identify an immediate reaction. Emergency medications and trained personnel must be available. A tolerated challenge supports removal of the penicillin allergy label.

Patients with a history concerning for anaphylaxis or another immediate IgE-mediated reaction generally warrant allergy evaluation. Penicillin skin testing can assess sensitization to major and minor determinants where validated reagents and expertise are available. A negative skin test is typically followed by an oral amoxicillin challenge because challenge confirms clinical tolerance. A positive skin test or convincing recent immediate reaction may justify continued avoidance when alternatives are acceptable.

Desensitization is not the same as delabeling. It produces temporary tolerance and is reserved for patients with confirmed or strongly suspected immediate allergy who require a specific penicillin because no acceptable alternative exists. It must be performed in a monitored setting using a validated protocol. Tolerance disappears after the drug is stopped, so the allergy label remains unless the patient later undergoes formal reevaluation.

After a negative challenge, complete the work. Remove the allergy from the active EHR allergy list, document the exact drug and dose tolerated, communicate the result to the patient and relevant clinicians, and address duplicate labels in pharmacy or outside records when possible. Patients should be told that future ordinary adverse effects do not automatically recreate an allergy label. If a delayed benign rash develops after a negative immediate challenge, reassessment may be needed, but this is different from immediate anaphylaxis.

Pregnancy is not an automatic reason to defer evaluation. Contemporary evidence supports risk-stratified penicillin allergy assessment during pregnancy when appropriate expertise and emergency readiness are available, which is particularly valuable when beta-lactams are likely to be needed for group B streptococcal prophylaxis, cesarean delivery, or syphilis treatment.

Epidemiology / Risk Factors

• Penicillin allergy is one of the most commonly documented drug allergies.
• Only a minority of patients carrying a penicillin allergy label have persistent clinically significant immediate hypersensitivity when formally evaluated.
• Labels acquired in childhood often persist into adulthood without reassessment.
• Inaccurate labels alter antibiotic prescribing and contribute to use of broader-spectrum agents.
• Delabeling programs are an important component of antimicrobial stewardship in hospitals and outpatient practice.

Investigations

Risk Examples

Pharmacology

Prognosis / Complications

• Most low-risk patients who complete an appropriate oral challenge tolerate penicillin and can be delabeled.
• A negative evaluation expands future antibiotic options and may reduce exposure to broader-spectrum alternatives.
• Patients with true immediate allergy may lose sensitization over time and can sometimes be reevaluated later.
• Severe delayed reactions require longer-term avoidance and specialist documentation because recurrence can be life-threatening.
• The benefit of testing is lost when the allergy label is not actually removed or reappears in disconnected medical records.

Patient Education / Counseling

• Explain the difference between allergy and expected adverse effects such as nausea or diarrhea.
• Tell patients that a negative supervised challenge demonstrates current tolerance to the tested drug.
• Provide written documentation of the successful challenge and encourage the patient to share it with pharmacies and other health systems.
• Do not tell patients with SJS, TEN, DRESS, or organ injury that a simple oral challenge is an appropriate way to test the allergy.
• If a future immediate reaction occurs after delabeling, seek urgent care and have the new event documented precisely.
• Emphasize that accurate allergy records improve antibiotic choices and are part of routine medical safety.

Notes

The practical goal of delabeling is not to prove that a patient can never react to penicillin in the future. Any person can develop a new drug allergy. The goal is to determine whether the existing historical label accurately predicts current clinically important hypersensitivity.

The safest programs separate low-risk direct challenge from high-risk specialist pathways. Collapsing every rash into one category creates two opposite errors: unnecessary avoidance in low-risk patients and unsafe challenge in patients with severe delayed disease.

References

1. AAAAI Penicillin Allergy Center and Drug Allergy: A 2022 Practice Parameter Update — Link
2. AAAAI Work Group Report: Penicillin Allergy Delabeling in Pregnancy, 2026 — Link